Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021 Escalated the Dose in RTX-240 Phase 1 ...
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is using its platform to genetically engineer red blood ...
Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for RTX-240 Phase 1/2 Solid Tumor Clinical Trial Investigational New Drug Application on Track by Year-End for RTX-321 for ...
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results